Clinical trial
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality…
NCT05556512 · Eli Lilly and Company, Industry · Active, not recruiting
Key facts
| NCT number | NCT05556512 |
|---|---|
| Title | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity |
| Official title | A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity |
| Acronym | SURMOUNT-MMO |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity, Overweight |
| Intervention type | Drug |
| Interventions | Tirzepatide, Placebo |
| Enrollment | 15,374 |
| Start date | Oct 11, 2022 |
| Primary completion | Oct 1, 2027 |
| Completion | Oct 1, 2027 |
| First posted | Sep 27, 2022 |
| Last update posted | Jan 12, 2026 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary and 16 more |
At a glance
- 1,000+ Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: